Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated Novel Swine Origin A/H3N2v Monovalent Subunit Influenza Virus Vaccine (H3N2c) in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly > 65 Years and Older

Trial Profile

Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated Novel Swine Origin A/H3N2v Monovalent Subunit Influenza Virus Vaccine (H3N2c) in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly > 65 Years and Older

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Influenza A virus vaccine-H3N2 (Primary) ; MF 59
  • Indications Influenza A virus H3N2 subtype
  • Focus Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 16 Feb 2016 Protocol has been amended to change in study design,end points and age crieteria.
    • 09 Oct 2014 Status changed from active, no longer recruiting to completed reported by ClinicalTrials.gov.
    • 18 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top